Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy

被引：0
|
作者：
Igor Bondarenko
Oleg A Gladkov
Reiner Elsaesser
Anton Buchner
Peter Bias
机构：
[1] State Medical Academy,Dnipropetrovsk
[2] Chelyabinsk Regional Clinical Oncology Center,undefined
[3] Teva Ratiopharm,undefined
来源：
BMC Cancer | / 13卷
关键词：
Neutropenia; Febrile neutropenia; Breast cancer; Recombinant granulocyte-colony stimulating factor; Lipegfilgrastim; Pegfilgrastim;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [11] Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study
    Oleg A. Gladkov
    Anton Buchner
    Peter Bias
    Udo Müller
    Reiner Elsässer
    Supportive Care in Cancer, 2016, 24 : 395 - 400
  • [12] IMMUNOGENICITY OF LIPEGFILGRASTIM AND PEGFILGRASTIM IN BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY: INTEGRATED ANALYSIS FROM PHASE II AND III STUDIES
    Abdolzade-Bavil, A.
    Zou, L.
    Sadhu, C.
    Buchner, A.
    Liu, P.
    HAEMATOLOGICA, 2013, 98 : 421 - 421
  • [13] Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial
    Masuda, Norikazu
    Tokuda, Yutaka
    Nakamura, Seigo
    Shimazaki, Ryutaro
    Ito, Yoshinori
    Tamura, Kazuo
    SUPPORTIVE CARE IN CANCER, 2015, 23 (10) : 2891 - 2898
  • [14] Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer
    Chan, S
    Friedrichs, K
    Noel, D
    Pintér, T
    Van Belle, S
    Vorobiof, D
    Duarte, R
    Gil, MG
    Bodrogi, I
    Murray, E
    Yelle, L
    von Minckwitz, G
    Korec, S
    Simmonds, P
    Buzzi, F
    Mancha, RG
    Richardson, G
    Walpole, E
    Ronzoni, M
    Murawsky, M
    Alakl, M
    Riva, A
    Crown, J
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) : 2341 - 2354
  • [15] Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial
    Norikazu Masuda
    Yutaka Tokuda
    Seigo Nakamura
    Ryutaro Shimazaki
    Yoshinori Ito
    Kazuo Tamura
    Supportive Care in Cancer, 2015, 23 : 2891 - 2898
  • [16] A MULTICENTER RANDOMIZED PHASE III STUDY OF KRN125 (PEGFILGRASTIM) IN BREAST CANCER PATIENTS RECEIVING TC CHEMOTHERAPY
    Rai, Y.
    Sagara, Y.
    Kuranami, M.
    Masuda, N.
    Takano, T.
    Saeki, T.
    Nakamura, S.
    Ito, Y.
    Tokuda, Y.
    Tamura, K.
    ANNALS OF ONCOLOGY, 2013, 24 : 13 - 13
  • [17] A randomized, multicenter clinical trial to determine the efficacy and safety of pegfilgrastim (GEMA BIOTECH) compared to pegfilgrastim (Roche) for prevention of chemotherapy induced neutropenia in patients with breast cancer.
    Eduardo Richardet, Martin
    Dario Kowalyszyn, Ruben
    Susana Varela, Mirta
    Ortiz, Eduardo
    Micheri, Cristian
    Jose Zarba, Juan
    Kahl, Susana
    Klimovsky, Ezequiel
    Alicia Federico, Andrea
    Enrique Fein, Luis
    Horacio Cassini, Jorge
    Cortese, Gustavo
    Visintini Jaime, Florencia
    Cordeiro, Lucas
    Ruben Lago, Nestor
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [18] Clinical Impact of Primary Prophylactic Pegfilgrastim in Breast Cancer Patients Receiving Adjuvant Docetaxel-Doxorubicin-Cyclophosphamide Chemotherapy
    Jeon, Ye Won
    Lim, Seung Taek
    Gwak, HongKi
    Park, Seon Young
    Suh, Young Jin
    JOURNAL OF BREAST CANCER, 2020, 23 (05) : 521 - 532
  • [19] Safety and efficacy of aerobic training in operable breast cancer patients receiving neoadjuvant chemotherapy: A phase II randomized trial
    Hornsby, Whitney E.
    Douglas, Pamela S.
    West, Miranda J.
    Kenjale, Aarti A.
    Lane, Amy R.
    Schwitzer, Emily R.
    Ray, Kaitlin A.
    Herndon, James E., II
    Coan, April
    Gutierrez, Antonio
    Hornsby, Kyle P.
    Hamilton, Erika
    Wilke, Lee G.
    Kimmick, Gretchen G.
    Peppercorn, Jeffrey M.
    Jones, Lee W.
    ACTA ONCOLOGICA, 2014, 53 (01) : 65 - 74
  • [20] Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: Results of a randomized, multicenter, phase III trial
    Nabholtz, JM
    Falkson, C
    Campos, D
    Szanto, J
    Martin, M
    Chan, S
    Pienkowski, T
    Zaluski, J
    Pinter, T
    Krzakowski, M
    Vorobiof, D
    Leonard, R
    Kennedy, I
    Azli, N
    Murawsky, M
    Riva, A
    Pouillart, P
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (06) : 968 - 975
12345